{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:47:34Z","timestamp":1747154854801,"version":"3.40.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.amjcard.2019.01.057","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T02:22:09Z","timestamp":1551147729000},"page":"1729-1731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-6332","authenticated-orcid":false,"given":"Ravi","family":"Rasalingam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7145-8084","authenticated-orcid":false,"given":"William E.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.01.057_bib0001","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0002","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0003","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.jacc.2018.08.2163","article-title":"Healthy behavior, risk factor control, and survival in the COURAGE trial","volume":"72","author":"Maron","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0004","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0005","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/CIR.0b013e3182776f83","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","article-title":"Expert consensus document: a \u201cdiamond\u201d approach to personalized treatment of angina","volume":"15","author":"Ferrari","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000487936","article-title":"Treatment of angina: where are we?","volume":"140","author":"Balla","year":"2018","journal-title":"Cardiology"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0008","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijcard.2016.06.150","article-title":"Medical treatment of stable angina: a tailored therapeutic approach","volume":"220","author":"Manolis","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0009","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/clc.22585","volume":"39","author":"Zarifis","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0010","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0011","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000439584","article-title":"Ivabradine in combination with metoprolol improves symptoms and quality of life in patients with stable angina pectoris: a post hoc analysis from the ADDITIONS Trial","volume":"133","author":"Werdan","year":"2016","journal-title":"Cardiology"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0012","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0013","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0015","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0017","unstructured":"Revascularization Rates and Associated Costs among Patients with Stable Ischemic Heart Disease Initiating Ranolazine versus Traditional Antianginals as Add-on Therapy."},{"key":"10.1016\/j.amjcard.2019.01.057_bib0018","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCINTERVENTIONS.112.000215","article-title":"Antianginal therapy before percutaneous coronary intervention","volume":"6","author":"Borden","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0019","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/CIRCULATIONAHA.114.013042","volume":"131","author":"Iqbal","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0020","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamainternmed.2014.3328","article-title":"How cardiologists present the benefits of percutaneous coronary interventions to patients with stable angina: a qualitative analysis","volume":"174","author":"Goff","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjcard.2019.01.057_bib0021","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1001\/archinte.167.15.1604","article-title":"Cardiologists' use of percutaneous coronary interventions for stable coronary artery disease","volume":"167","author":"Lin","year":"2007","journal-title":"Arch Intern Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919302401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919302401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T07:59:01Z","timestamp":1556611141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919302401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0002914919302401"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.01.057","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.01.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}